If year-to-date performance were the deciding factor on which stock to buy, there would be no contest between Aphria (NASDAQOTH:APHQF) and MariMed(NASDAQOTH:MRMD). Aphria has lost nearly half of its market cap.

One of Canada’s largest cannabis companies announced Wednesday it has received Health Canada approval for clinical trials of the effectiveness of cannabis-derived compound cannabidiol as a treatment for anxiety in animals.

Dana M. Vaughn, executive vice-president and chief scientific officer for Canopy Animal Health, said while CBD is becoming an increasingly common folk remedy for pets’ ailments, Canopy’s clinical trials represent the first time a company has sought federal regulatory approval for the practice of adding the substance to pet food.

THC BioMed Intl Ltd. ("THC" or the "Company") (CSE:THC) announces that it has developed a cannabis beverage that mimics alcohol in that the uplifting and energizing effects of the cannabis is felt by the consumer in a short period of time. THC believes that this beverage is a solution to a major problem with cannabis beverages and edibles, as current products cause fatigue and drowsiness.

Metro Vancouver’s municipal leaders are bracing for a significant increase in odour complaints when marijuana is legalized this fall.

This follows a sudden spike in the number of complaints the regional district has received involving a legal commercial cannabis grow operation that recently started operating in Langley.

“Here we have a new industry that’s in its infancy in terms of being legal, and now it’s out in the open and it needs to be dealt with like any other industry. They’re not going away,” said Township of Langley Mayor Jack Froese.

Marijuana legislation was passed earlier this year and recreational pot sales are expected to commence in mid-October, and while medical marijuana has been legalized for some time now, it too could benefit from the new law. It’s not as if companies are struggling to sell medical marijuana, but legalization will make it easier for patients and those looking for the benefits of cannabidiol to get easier access to cannabis. Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) and others in the industry have had to rely on medicinal sales so far, and while there has been grown in that segment, there’s clearly much…

At the Village Bloomery cannabis dispensary in Vancouver, Andrea Dobbs sometimes meets clients in search of a heavy dose of THC to ease the strain of cancer treatments or the pain of endometriosis.

If the client is new to cannabis, or physically frail, Dobbs might suggest cannabis suppositories, inserted directly into the rectum or vagina.

Village Bloomery co-founders Jeremy Jacob and Andrea Dobbs at their Vancouver cannabis dispensary.

CSTAR Cannabis Inc. ("CSTAR Cannabis") is pleased to announce that its application to become a Licensed Producer ("LP") under Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR") has progressed to the 'Active Review' Stage. This progress places CSTAR Cannabis in the final stage of the ACMPR application process, preceding the issuance of a License to Produce. Meanwhile, CSTAR Cannabis continues to work closely with Health Canada to complete its high technology production facility, designed to cultivate craft cannabis products and develop unique proprietary genetics.   

Spruce Grove, Alta., resident Darryl Kolewaski, who takes medical marijuana for arthritis, said his THC levels are consistently more than 10 times higher than that threshold.

“When I wake up in the morning, after not medicating since the night before I went to bed, I wake up with 25 nanograms in my blood. So that’s a huge concern to me if they’re swabbing you,” Kolewaski said.

“Later in the day, I’ve gone as high as 70 or 80 nanograms — none of that, however, being (impairing) to me. I’m not unable to operate or function. I can function completely normally.”

Partner and chair of the Employment and Labour Group at Gardiner Roberts LLP, author of the Halsbury’s Laws of Canada volume on Employment Law and the volume on Discrimination and Human Rights

This October, the legal, social and political landscapes of Canada will change dramatically when the purchase of recreational cannabis becomes legal. The latest data suggest roughly one in 10 Canadians were cannabis users in the past year, meaning few workplaces across the country will not be affected.

With employers still grappling with the complexity of managing addiction in the workplace as it pertains to alcohol and other drugs, the legalization of pot will add another hurdle.

Story continues below advertisement

The Horizons Marijuana Life Sciences ETF (TSX:HMMJ) was down 1.21% in early afternoon trading on August 7. Cannabis stocks have been battered since recreational legalization was made official in late June. The federal government set the date of October 17 for this to come into effect.

The Horizons Marijuana Life Sciences ETF has dropped 14% in 2018 so far. Valuations for the largest cannabis producers in Canada have soared since the Liberal government came to power in 2015, partly on the back of a promise to push for legalization.